Results 141 to 150 of about 3,454 (177)

Pharmacologic and clinical profile of dexamethasone intravitreal implant

Expert Review of Clinical Pharmacology, 2012
The challenge in the treatment of chronic retinal diseases is to deliver effective therapy to the target tissues in the back of the eye while limiting drug exposure in nontarget tissues. Intravitreal placement provides the most targeted drug delivery, but repeated penetration of the globe to deliver intravitreal therapy can pose safety risks.
Michael R, Robinson, Scott M, Whitcup
openaire   +2 more sources

Intravitreal slow-releasing dexamethasone implant for idiopathic neuroretinitis

European Journal of Ophthalmology, 2020
Introduction: The purpose of this report is to describe a successful management of idiopathic neuroretinitis with intravitreal dexamethasone implant. Method: Interventional case report.
Osman Çekiç, Samet Gülkaş
openaire   +3 more sources

Intravitreal dexamethasone implant for noninfectious uveitis in Chinese patients

International Ophthalmology, 2022
To evaluate the effectiveness and safety of the dexamethasone intravitreal implant (DEX-I) in Non-Infectious Uveitis (NIU) in Chinese patients.Ninety-one eyes of 77 patients (56 men, 21 women) receiving 130 implant injections for NIU were included. Treatment indication, uveitis diagnosis, best-corrected visual acuity (BCVA), central retinal thickness ...
Shun Zeng, Li Yang, Feng Bai, Tao Liu, Xiaoli Liu   +4 more
openaire   +2 more sources

Intravitreal Dexamethasone Implant for Treatment of Sarcoidosis-Related Uveitis

Advances in Therapy, 2019
To assess the efficacy and safety of intravitreal dexamethasone implant injection in the management of sarcoidosis-related uveitis.A retrospective analysis was performed of the efficacy and safety of intravitreal dexamethasone implant injection for indications such as intractable vitritis, vasculitis, or cystoid macular edema.This study comprised 20 ...
Mirinae Kim, Seong Ah Kim, Wookyung Park, Rae Young Kim, Young-Hoon Park   +4 more
openaire   +2 more sources

Intravitreal dexamethasone implant in radiation-induced macular oedema

British Journal of Ophthalmology, 2017
To evaluate the efficacy and duration of activity of a single intravitreal dexamethasone implant in patients affected by radiation maculopathy.Thirteen consecutive eyes of 13 patients affected by radiation maculopathy secondary to eye irradiation for a primary uveal melanoma (Iodine-125 brachytherapy) and treated with a single intravitreal 0.7 mg ...
Frizziero, Luisa, PARROZZANI, RAFFAELE, Trainiti, Sara, PILOTTO, ELISABETTA, Miglionico, Giacomo, Pulze, Serena, MIDENA, EDOARDO   +6 more
openaire   +2 more sources

Dexamethasone: intravitreal implant.

Prescrire international, 2011
Macular oedema is one of the complications of retinal vein occlusion. About half of the patients recover spontaneously within 3 to 6 months. There is currently no drug that improves outcome. An intravitreal implant delivering 0.7 mg of dexamethasone has been authorised for the treatment of macular oedema in this setting. Clinical assessment is based on
openaire   +1 more source

Intravitreal Dexamethasone Implant for the Treatment of Postoperative Macular Edema

Ophthalmologica, 2016
<b><i>Introduction:</i></b> Macular edema after cataract surgery (Irvine-Gass syndrome) or pars plana vitrectomy is a postoperative complication which can lead to permanent visual loss. Increased inflammatory substances, such as prostaglandins and cytokines, are discussed to be causative.
André, Klamann, Katharina, Böttcher, Philipp, Ackermann, Gerd, Geerling, Marc, Schargus, Rainer, Guthoff   +5 more
openaire   +2 more sources

Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis

Archives of Ophthalmology, 2011
To evaluate the safety and efficacy of 2 doses of dexamethasone intravitreal implant (DEX implant) for treatment of noninfectious intermediate or posterior uveitis.In this 26-week trial, eyes with noninfectious intermediate or posterior uveitis were randomized to a single treatment with a 0.7-mg DEX implant (n = 77), 0.35-mg DEX implant (n = 76), or ...
Lowder, C., Belfort, R., Lightman, S., Foster, C.S., Robinson, M.R., Schiffman, R.M., Li, X.Y., Cui, H., Whitcup, S.M.   +8 more
openaire   +3 more sources

DEXAMETHASONE INTRAVITREAL IMPLANT FOR CHOROIDAL NEOVASCULARIZATION DURING PREGNANCY

RETINAL Cases & Brief Reports, 2019
Purpose: To describe the management of active choroidal neovascularization (CNV) during pregnancy with the use of a dexamethasone intravitreal implant (DXI) (Ozurdex). Methods: Case series of active CNV treated with DXI with at least 12-month follow-up retrospectively analyzed at 2 ...
Capuano V., Serra R., Oubraham H., Zambrowski O., Amana D., Zerbib J., Souied E. H., Querques G.   +7 more
openaire   +3 more sources

EFFECT OF INTRAVITREAL DEXAMETHASONE IMPLANT ON THE CONTRALATERAL EYE

RETINAL Cases & Brief Reports, 2013
Purpose: To describe the effect of unilateral intravitreal injection of 0.7-mg dexamethasone implant on the other eye. Methods: Interventional case report and literature review. Results: A 54-year-old woman with bilateral, refractory ...
Ashish, Sharma, Jay, Sheth, Rangasamy J, Madhusudan, Selva K, Sundaramoorthy   +3 more
openaire   +2 more sources